PLC
BCYC

Peapod Lane Capital’s Bicycle Therapeutics BCYC Stock Holding History

Peapod Lane Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Buy
537,978
+416,872
+344% +$1.91M 1.54% 27
2026
Q1 		$550K Buy
+121,106
New +$692K 0.45% 60

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Peapod Lane Capital's BCYC Position: Q2 2026 in Review

Peapod Lane Capital increased its Bicycle Therapeutics (BCYC) stake by 344% in Q2 2026, buying an estimated $1.91M and bringing the position to 537,978 shares worth $2.28M. The position accounts for 1.54% of the portfolio, ranked #27.

Peapod Lane Capital first reported a position in BCYC in Q1 2026 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Peapod Lane Capital held 537,978 shares of Bicycle Therapeutics worth $2.28M as of Q2 2026.
  • Peapod Lane Capital bought 416,872 Bicycle Therapeutics shares in Q2 2026, an estimated $1.91M.
  • Bicycle Therapeutics made up 1.54% of Peapod Lane Capital's portfolio in Q2 2026, its #27 holding.
  • Peapod Lane Capital first reported a position in Bicycle Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.